EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The role of vascular adhesion protein‐1 in diabetes and diabetic complications

I-Weng Yen, Hung-Yuan Li iD

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14209 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von I-Weng Yen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Hauptthemen laut MEDLINE: Amine Oxidase (Copper-Containing), Cell Adhesion Molecules, Diabetes Complications. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular adhesion protein‐1 (VAP‐1) plays a dual role with its adhesive and enzymatic properties, facilitating leukocyte migration to sites of inflammation and catalyzing the breakdown of primary amines into harmful by‐products, which are linked to diabetic complications. Present in various tissues, VAP‐1 also circulates in a soluble form in the bloodstream. Diabetes is associated with several complications such as cardiovascular disease, retinopathy, nephropathy, and neuropathy, significantly contributing to disability and mortality. These complications arise from hyperglycemia‐induced oxidative stress, inflammation, and the formation of advanced glycation end‐products (AGEs). Earlier research, including our own from the 1990s and early 2000s, has underscored the critical role of VAP‐1 in these pathological processes, prompting extensive investigation into its contribution to diabetic complications. In this review, we examine the involvement of VAP‐1 in diabetes and its complications, alongside its link to other conditions related to diabetes, such as cancer and metabolic dysfunction‐associated fatty liver disease. We also explore the utility of soluble VAP‐1 as a biomarker for diabetes, its complications, and other related conditions. Since the inhibition of VAP‐1 to treat diabetic complications is a novel and promising treatment option, further studies are needed to translate the beneficial effect of VAP‐1 inhibitors observed in animal studies to clinical trials recruiting human subjects. Besides, future studies should focus on using serum sVAP‐1 levels for risk assessment in diabetic patients, identifying those who need intensive glycemic control, and determining the patient population that would benefit most from VAP‐1 inhibitor therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amine Oxidase (Copper-Containing)Cell Adhesion MoleculesDiabetes ComplicationsHumansAnimalsDiabetes MellitusBiomarkersGlycation End Products, Advanced

Stichwörter der Autor:innen

Vascular adhesion protein‐1diabetic complicationssemicarbazide‐sensitive amine oxidase

Substanzen

Amine Oxidase (Copper-Containing)AOC3 protein, humanCell Adhesion MoleculesBiomarkersGlycation End Products, Advanced

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Hung-Yuan Li

Zitieren

APA

Yen, I. W., & Li, H. Y. (2024). The role of vascular adhesion protein‐1 in diabetes and diabetic complications. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14209

Vancouver

Yen IW, Li HY. The role of vascular adhesion protein‐1 in diabetes and diabetic complications. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14209

BibTeX
@article{Yen2024,
  author = {Yen, I-Weng and Li, Hung-Yuan},
  title = {The role of vascular adhesion protein‐1 in diabetes and diabetic complications},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14209}
}
Kostenlos starten →